lavoltidine lavoltidine lavoltidine (inn, usan, ban; previously known as loxtidine, code name ah-23,844) is a highly potent and selective h2 receptor antagonist which was under development by glaxo wellcome (now glaxosmithkline) as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents. lavoltidineclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status development terminated identifiers iupac name propylamino]-1,2,4-triazol-3-yl]methanol cas number76956-02-0pubchem cid55473chemspider50093uniix16k5179v5comptox dashboard (epa)dtxsid0020785 chemical and physical dataformulac19h29n5o2molar mass359.474 g·mol−13d model (jsmol)interactive image smiles occ1nn(c)c(n1)ncccoc2cccc(c2)cn3ccccc3